Products for Research Use Only
RegisterLogin

Topiroxostat

CAT: 0013-GTR19174938-05Size: 200 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0013-GTR19174938-05Size:200 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Topiroxostat (FYX-051) is a potent and selective xanthine oxidase inhibitor used in research on hyperuricemia and gout. It has demonstrated efficacy in both in vitro enzymatic assays and in vivo animal models, effectively lowering serum urate levels.
CAS Number
577778-58-6
Product Name Alternative
CYP3A4, CYPs, Cytochrome P450, Asn 768, acid, inhibit, Inhibitor, hyperuricemia, FYX 051, FYX051, FYX-051, XOR, XO, XanthineOxidase, Xanthine Oxidase, pharmacokinetic, Topiroxostat, uric
Field of Research
Immunology & Inflammation, Metabolism Research, Pharmacology & Drug Discovery
Purity
98.95% (May vary between batches)
Solubility
DMSO:11 mg/mL (44.31 mM)
Smiles
N#Cc1cc (ccn1) -c1nc (n[nH]1) -c1ccncc1
Molecular Formula
C13H8N6
Molecular Weight
248.24
Storage Conditions
-20°C
Notes
For research use only.

Chemical Information

Topiroxostat

Topiroxostat is a selective xanthine oxidase inhibitor developed for treatment and management of hyperuricemia and gout. Xanthine oxidase, or xanthine oxidoreductase (XOR), regulates purine metabolism, and inhibition of the enzyme results in efficacious reduction of serum urate levels. Xanthine oxidase inhibitors are classified into two groups; purine analogs such as [DB00437] and [DB05262], and non-purine agents which includes topiroxostat. While [DB00437] is considered a first-line therapy in treating hyperuricemic conditions, it is often associated with side effects and ineffective in reducing uric acid levels under recommended dosing regimens. Renal complications are major comorbidities that limit the [DB00437] therapy as dose reductions are recommended. Topiroxostat and its metabolites are shown to be unaffected by renal complications, thus may be effective in patients with chronic kidney diseases. Approved for therapeutic use in Japan since 2013, topiroxostat is marketed under the name Topiloric and Uriadec and is orally administered twice daily.

CAS Number577778-58-6
PubChem CID5288320
IUPAC Name4-(5-pyridin-4-yl-1H-1,2,4-triazol-3-yl)pyridine-2-carbonitrile
Molecular FormulaC13H8N6
Molecular Weight248.24
XLogP1.2
Topological Polar Surface Area91.1
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count5
Rotatable Bond Count2
Heavy Atom Count19
Formal Charge0
Complexity344
SMILES
C1=CN=CC=C1C2=NC(=NN2)C3=CC(=NC=C3)C#N
InChI
InChI=1S/C13H8N6/c14-8-11-7-10(3-6-16-11)13-17-12(18-19-13)9-1-4-15-5-2-9/h1-7H,(H,17,18,19)
InChIKey
UBVZQGOVTLIHLH-UHFFFAOYSA-N
Chemical Structure
2D Structure
2D structure of Topiroxostat
CAS: 577778-58-6
CID: 5288320
Formula: C13H8N6
MW: 248.24
Interactive 3D Structure
Loading 3D structure...
View on PubChemRaw 3D data
Computed Properties
PropertyValue
Molecular Weight248.24
XLogP31.2
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count5
Rotatable Bond Count2
Exact Mass248.08104428
Monoisotopic Mass248.08104428
Topological Polar Surface Area91.1 Ų
Heavy Atom Count19
Formal Charge0
Complexity344
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count1
Compound Is CanonicalizedYes

Alternative Products

CatalogName
B1192-10Topiroxostat
TMIJ-0129-01Topiroxostat-d4
RM-T161801-01Topiroxostat Impurity A
CS-T-94273Topiroxostat ACID
HY-14874R-01Topiroxostat (Standard)

Popular Products